Research survey on CLL/SLL: Hi We are doing some... - CLL Support

CLL Support

23,324 members40,026 posts

Research survey on CLL/SLL

bkoffman profile image
bkoffmanCLL CURE Hero
8 Replies

Hi

We are doing some research in follow up to our abstract from ASH 2016 and would appreciate your help.

Participate in an important Survey for Patients with CLL/SLL

• Have you been diagnosed with chronic lymphocytic leukemia or small lymphocytic lymphoma?

• Do you reside in the United States?

If the answer to both questions is “yes”, please read below.

The CLL Society Inc. (CLLS) is conducting a research survey. The purpose of the survey is to help us better understand how CLL/SLL (chronic lymphocytic leukemia/small lymphocytic lymphoma) and the treatments you receive have affected your life and the lives of those around you. Your answers will be used to improve our services and patient programs—and possibly how doctors treat CLL/SLL.

Your answers will be 100% confidential, and no personal identifying information will be collected within the survey. The answers you and other patients provide will be carefully combined and analyzed to create an overall picture of how CLL and its treatment affect the lives of people with CLL. Our goal is to understand CLL from the patient’s perspective.

At the end of the survey you can choose to participate in the Target gift code offer. The first 500 patients who complete the entire survey will be eligible to receive a $50 gift code that can be spent on the Target.com website, or used within their stores.

You can participate in one of two ways:

Access the Online Survey HERE: cllpatient.questionpro.com

OR

Request a Paper Survey by calling 949-667-4CLL or send an email to research@cllsociety.org and provide your name and address and a survey will be mailed to you.

Questions? Email us at research@cllsociety.org or call 949-667-4CLL.

Your Voice Matters! We hope to publish the results and post abstracts at ASCO and ASH. We want providers to know what we rethinking and what we want.

Thanks

Stay strong. We are all in this together

Brian Koffman, MD

Written by
bkoffman profile image
bkoffman
CLL CURE Hero
To view profiles and participate in discussions please or .
Read more about...
8 Replies
Yorkiemama profile image
Yorkiemama

Done!

bkoffman profile image
bkoffmanCLL CURE Hero in reply toYorkiemama

Thanks.

Yorkiemama profile image
Yorkiemama in reply tobkoffman

Easy to answer, good questions too! Thank you as always.

Cynthia

Filled it out yesterday. Hope it helps to know what we face at diagnosis and beyond. It is a worthwhile survey. Thanks. Sally

bkoffman profile image
bkoffmanCLL CURE Hero in reply toCLLCalifornia-USA

Thanks for doing it and your words of support.

gardening-girl profile image
gardening-girl

Dr. Koffman, I just completed the survey and found that it was not possible to enter treatments that were not listed, even though we were asked to do so: "Other outside a clinical trial (please list the therapy)" There is no place available to list "other" therapies.

Thanks for all you do!

NWcllfighter profile image
NWcllfighter

Survey closed when checked on 9/3/18.

bkoffman profile image
bkoffmanCLL CURE Hero

It is long closed. Sorry, but we will be doing more research next year

Not what you're looking for?

You may also like...

ATTENTION CLL + SLL PATIENTS AND CAREGIVERS

Lymphoma Canada and the CLL Patient Advocacy Group (CLLPAG) is preparing a submission for the...
LCAdmin profile image

Results on triple combination (A+V+O) for high risk patients -with-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-cll

The Bottom Line: In this ongoing trial, the triple combination therapy using acalabrutinib,...
spi3 profile image

CLL SOCIETY'S ASH POSTER on our Free second opinion program plus two important papers from ASCO

Hi, Just back from a frenetic and fantastic ASH, but still have news to share from ASCO. But first...
bkoffman profile image
CLL CURE Hero

FDA Approves Venetoclax (VENCLEXTA) For CLL or SLL with or without 17p deletion, who have received at least one prior therapy

FDA Approves Venetoclax (VENCLEXTA) For Chronic Lymphocytic Leukemia or Small Lymphocytic...
lankisterguy profile image
Volunteer

EHA 2022: Outcomes Following Treatment With a Covalent BTK and BCL2 Inhibitor

https://cllsociety.org/2022/08/eha-2022-outcomes-following-treatment-with-a-covalent-btk-and-bcl2-in

Moderation team

See all
CLLerinOz profile image
CLLerinOzAdministrator
AussieNeil profile image
AussieNeilAdministrator
Newdawn profile image
NewdawnAdministrator

Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.

Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.